{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62","upperLimit":"97","value":"77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"}],"units":"Participants"}],"description":"Phase II: 3-year Relapse-free survival assessed using the Kaplan-Meier method, defined as the time from completion of standard of care definitive therapy to the date of disease recurrence or death (any cause) whichever occurs first. Participants who receive two doses of PRGN-2009 and go on to receive standard definitive therapy will be evaluable for overall survival assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Phase II in newly diagnosed, untreated, locoregional p16-positove oropharyngeal cancer (OPC) (cohort 2) and in newly diagnosed. Arm 2A: HPV vaccine at recommended phase 2 dose (RP2D) as determined at completion of Arm 1A. HPV vaccine at 5x10\\^11 Viral Particles (VP).","id":"OG000","title":"Phase II Cohort 2, Arm 2A, Dose Level 2"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"3 years","title":"Phase II: 3 Year Relapse-free Survival for PRGN-2009 Alone","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}